BRAF and PRKCE

Number of citations of the paper that reports this interaction (PubMedID 16810323)
65

Data Source:
HPRD (in vivo)

		BRAF	PRKCE
Description		B-Raf proto-oncogene, serine/threonine kinase	protein kinase C epsilon
Image
GO Annotations	Cellular Component	Nucleus Mitochondrion Cytosol Plasma Membrane Intracellular Membrane-bounded Organelle	Nucleus Cytoplasm Mitochondrion Endoplasmic Reticulum Golgi Apparatus Cytosol Cytoskeleton Plasma Membrane Perinuclear Region Of Cytoplasm Cell Periphery
	Molecular Function	Protein Kinase Activity Protein Serine/threonine Kinase Activity Calcium Ion Binding Protein Binding ATP Binding Small GTPase Binding Identical Protein Binding	Actin Monomer Binding Protein Serine/threonine Kinase Activity Protein Kinase C Activity Calcium-dependent Protein Kinase C Activity Calcium-independent Protein Kinase C Activity Protein Binding ATP Binding Enzyme Activator Activity Enzyme Binding Receptor Activator Activity Ethanol Binding Metal Ion Binding 14-3-3 Protein Binding
	Biological Process	MAPK Cascade Activation Of MAPKK Activity Protein Phosphorylation Animal Organ Morphogenesis Positive Regulation Of Gene Expression Positive Regulation Of Glucose Transmembrane Transport Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of ERK1 And ERK2 Cascade Trehalose Metabolism In Response To Stress Cellular Response To Calcium Ion Establishment Of Protein Localization To Membrane	Macrophage Activation Involved In Immune Response Protein Phosphorylation Apoptotic Process Cell Cycle Cell Adhesion Signal Transduction Positive Regulation Of Epithelial Cell Migration Positive Regulation Of Fibroblast Migration Positive Regulation Of Cell-substrate Adhesion Peptidyl-serine Phosphorylation Platelet Activation Positive Regulation Of Actin Filament Polymerization Negative Regulation Of Protein Ubiquitination Lipopolysaccharide-mediated Signaling Pathway Positive Regulation Of Insulin Secretion Positive Regulation Of Synaptic Transmission, GABAergic Positive Regulation Of Cytokinesis Intracellular Signal Transduction Locomotory Exploration Behavior TRAM-dependent Toll-like Receptor 4 Signaling Pathway Fc-gamma Receptor Signaling Pathway Involved In Phagocytosis Positive Regulation Of Catalytic Activity Positive Regulation Of I-kappaB Kinase/NF-kappaB Signaling Response To Morphine Positive Regulation Of MAPK Cascade Regulation Of Peptidyl-tyrosine Phosphorylation Positive Regulation Of Lipid Catabolic Process Regulation Of Release Of Sequestered Calcium Ion Into Cytosol Cell Division Regulation Of Insulin Secretion Involved In Cellular Response To Glucose Stimulus Positive Regulation Of Mucus Secretion Cellular Response To Ethanol Cellular Response To Prostaglandin E Stimulus Cellular Response To Hypoxia Positive Regulation Of Wound Healing Positive Regulation Of Protein Localization To Plasma Membrane Negative Regulation Of Sodium Ion Transmembrane Transporter Activity Positive Regulation Of Cellular Glucuronidation
Pathways		Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants	Effects of PIP2 hydrolysis SHC1 events in ERBB2 signaling DAG and IP3 signaling Role of phospholipids in phagocytosis G alpha (z) signalling events
Drugs		Sorafenib XL281 N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib	Tamoxifen KAI-1455
Diseases		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma
GWAS		anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Bipolar disorder ( 31043756) Cerebrospinal fluid t-tau:AB1-42 ratio ( 26252872) Cerebrospinal T-tau levels ( 26252872) Mild influenza (H1N1) infection ( 26379185) Response to Vitamin E supplementation ( 22437554) Type 2 diabetes ( 28869590)	Body mass index ( 28552196) Carotenoid levels (alpha-carotene) ( 28002826) Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging) ( 26252872) Coronary artery disease ( 29212778) Corpus callosum posterior volume ( 31530798) Craniofacial microsomia ( 26853712) Diastolic blood pressure ( 28135244 30578418) Diisocyanate-induced asthma ( 25918132) Heel bone mineral density ( 30598549) Hematocrit ( 29403010 28453575 27863252 28017375 19862010) Hematological and biochemical traits ( 20139978) Hemoglobin ( 29403010 28453575 19862010) Hemoglobin concentration ( 27863252) Hemoglobin levels ( 28017375) High light scatter reticulocyte count ( 27863252) LDL cholesterol ( 30275531) Metabolite levels ( 23823483) Metabolite levels (X-11787) ( 23934736) Pathological gambling ( 27315593) Premature menopause in childhood cancer survivors ( 29432556) Pulse pressure ( 28135244 27841878 30578418) Red blood cell count ( 29403010 20139978 27863252 28017375) Red blood cell traits ( 23446634 23222517) Response to zileuton treatment in asthma (FEV1 change interaction) ( 26031901) Suicide risk ( 21041247) Systolic blood pressure ( 30578418) Total cholesterol levels ( 30275531) Triiodothyronine levels ( 30824882) Two-hour glucose in pregnancy (gestational week 30-32) ( 30324795) Venous thromboembolism adjusted for sickle cell variant rs77121243-T ( 28203683) Weight ( 28552196)
Interacting Genes		39 interacting genes: AKT1 ARAF AURKA BAD CCDC88A HRAS ITCH KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAPK1 MRAS NANOG OIP5 PAK2 PPP2CA PPP2R2A PRKACA PRKCE RAF1 RAP1A RAP1GAP RASSF1 RHEB SFN SGK1 SPRY2 STK11 TERF1 TERT UBE2L3 YWHAB YWHAG YWHAH YWHAQ YWHAZ	59 interacting genes: ACTA1 ACTC1 ADAP1 AFAP1 AKAP9 ATF2 BRAF BTK CFTR CHAT CNN1 COPB1 COPB2 DSP EGFR ELAVL1 FYN GAD1 GAD2 GJA1 GNA12 GNA13 GRIN1 GRIN2D GRM5 H1-1 HK2 IKBKB ITGB1 ITGB2 KRT1 KRT18 MAP4K4 MAPK1 MAPK3 MAPT MARK2 MYH2 NANOG NUMB OPRD1 PDLIM5 PDPK1 PECAM1 PIK3CB PPP1R14A PRKD1 RACK1 RAD9A RAF1 RASGRP3 RPS6KB2 SLC25A4 SLC4A3 SNCA SRC TIAM1 TRPV1 VDAC1
Entrez ID		673	5581
HPRD ID		01264	01500
Ensembl ID		ENSG00000157764	ENSG00000171132
Uniprot IDs		A0A2R8Y8E0 P15056	L7RTI5 Q02156
PDB IDs		1UWH 1UWJ 2FB8 2L05 3C4C 3D4Q 3IDP 3II5 3NY5 3OG7 3PPJ 3PPK 3PRF 3PRI 3PSB 3PSD 3Q4C 3Q96 3SKC 3TV4 3TV6 4CQE 4DBN 4E26 4E4X 4EHE 4EHG 4FC0 4FK3 4G9C 4G9R 4H58 4JVG 4KSP 4KSQ 4MBJ 4MNE 4MNF 4PP7 4R5Y 4RZV 4RZW 4WO5 4XV1 4XV2 4XV3 4XV9 4YHT 5C9C 5CSW 5CSX 5CT7 5FD2 5HI2 5HID 5HIE 5ITA 5J17 5J18 5J2R 5JRQ 5JSM 5JT2 5VAL 5VAM 5VR3 5VYK 6B8U 6CAD 6N0P 6N0Q 6NSQ 6NYB 6PP9 6Q0J 6Q0K 6Q0T 6U2G 6U2H 6UAN	2WH0 5LIH
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?